Skip to main content
main-content

Breast cancer

13-11-2017 | Oncology | Highlight | Article

Editor's pick

Long-term breast cancer recurrence risk linked to original TN status

The risk for breast cancer recurrence increases at a steady rate for at least 15 years after the end of planned endocrine therapy and is strongly associated with the original tumor diameter and nodal status, meta-analysis data show.

Source:

N Engl J Med 2017; 377: 1836–1846

09-11-2017 | Oncology | News | Article

Substantial variations in global young adult cancer burden revealed

Among young adults, the global incidence of cancer and associated mortality varies considerably by demographic factors and socioeconomic development levels, indicates research published in The Lancet Oncology.

Source:

Lancet Oncol 2017; Advance online publication

24-10-2017 | Breast cancer | News | Article

No rationale for extended anastrazole in early breast cancer

Extended use of anastrozole beyond 5 years of sequential adjuvant therapy does not significantly prolong disease-free survival in the majority of postmenopausal women with hormone receptor-positive early breast cancer, Dutch researchers report.

Source:

Lancet Oncol 2017; Advance online publication

04-10-2017 | Breast cancer | News | Article

Long-term insulin glargine use may increase breast cancer risk

Long-term use of the long-acting insulin analog glargine is associated with an increased risk for breast cancer in women with type 2 diabetes compared with the intermediate-acting neutral protamine Hagedorn insulin, observational study data show.

Source:

J Clin Oncol 2017; Advance online publication

02-10-2017 | Oncology | Main feed | News

approvalsWatch

Abemaciclib receives FDA approval

Click through to read more

12-09-2017 | Breast cancer | News | Article

ESMO 2017

First-line abemaciclib supported for HR+HER2– advanced breast cancer

Results from the MONARCH 3 study give support to first-line use of the oral selective CDK4/6 inhibitor abemaciclib, taken alongside nonsteroidal aromatase inhibitor therapy, in patients with advanced hormone receptor-positive, human epidermal growth factor receptor 2-negative breast cancer.

image credits